Zhengye Biotechnology Holding Ltd cash flow statement

In fiscal 2025, Zhengye Biotechnology Holding Ltd's operations generated $1.9m of cash; it spent $140,260 on capital projects, leaving free cash flow of $1.7m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Zhengye Biotechnology Holding Ltd: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	2,581	6,809	5,705	1,855
Depreciation and amortisation	2,800	3,379	3,358	3,602
Capital spending	4,069	1,045	1,888	140
Free cash flow	−1,488	5,764	3,816	1,715
Dividends paid	3,190	5,575	2,227	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: SLGL vs ZYBT JAGX vs ZYBT VRCA vs ZYBT

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Zhengye Biotechnology Holding Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Zhengye Biotechnology Holding Ltd.